The transcription initiation pathway of sigma 54 mutants that bypass the enhancer protein requirement. Implications for the mechanism of activation.
In vitro transcription, DNase I footprinting, and abortive initiation assays were used to characterize transcription using mutant forms of sigma 54 shown previously to bypass certain enhancer requirements in vitro. The holoenzymes containing these sigma mutants produce low levels of open complexes at both the glnAp2 and glnHp2 promoters. The open complexes are unusual in that they are destroyed by heparin. Enhancer protein and ATP convert them into a stable heparin-resistant state. The enhancer response occurs over a similar range of NtrC concentration as occurs with the wild-type holoenzyme, indicating that the activation determinants have been largely preserved within these mutants. One-round transcription assays show that the mutant holoenzymes can be driven to transcribe both promoters without NtrC. The unstable opening induced by these mutations apparently serves as a conduit that can shuttle templates into transcriptionally competent complexes. The results lead to a model in which activation occurs in two steps. First, the enhancer complex overcomes an inhibitory effect of the sigma 54 leucine patch and unlocks the melting activity of the holoenzyme. Second, different sigma 54 determinants are used to drive stabilization of the open complexes, allowing the full transcription potential to be realized.
Wang
J T
JT
Department of Chemistry and Biochemistry and the Molecular Biology Institute, University of California, Los Angeles, California 90095, USA. gralla@ewald.mbi.ucla.edu
Gralla
J D
JD
D000255:Adenosine Triphosphate / Q000378:metabolism; D001426:Bacterial Proteins / Q000502:physiology; D018983:DNA Footprinting; D004268:DNA-Binding Proteins / Q000502:physiology*; D012321:DNA-Directed RNA Polymerases / Q000737:chemistry / Q000502:physiology*; D004742:Enhancer Elements, Genetic; D015964:Gene Expression Regulation, Bacterial; D005974:Glutamate-Ammonia Ligase / Q000502:physiology; D006493:Heparin / Q000494:pharmacology; D034982:Integration Host Factors; D007930:Leucine; D046911:Macromolecular Substances; D051922:PII Nitrogen Regulatory Proteins; D012808:Sigma Factor / Q000502:physiology*; D013329:Structure-Activity Relationship; D015534:Trans-Activators; D014157:Transcription Factors; D014158:Transcription, Genetic
D001426:Bacterial Proteins; D004268:DNA-Binding Proteins; D034982:Integration Host Factors; D046911:Macromolecular Substances; D051922:PII Nitrogen Regulatory Proteins; D012808:Sigma Factor; D015534:Trans-Activators; D014157:Transcription Factors; D000255:Adenosine Triphosphate; D006493:Heparin; D012321:DNA-Directed RNA Polymerases; C081173:glutamine synthetase I; D005974:Glutamate-Ammonia Ligase; D007930:Leucine